Научная литература
booksshare.net -> Добавить материал -> Медицина -> Насонов Е.Л. -> "Антифосфолипидный синдром" -> 177

Антифосфолипидный синдром - Насонов Е.Л.

Насонов Е.Л. Антифосфолипидный синдром — М.: Литтерра, 2004. — 440 c.
ISBN 5-98216-010-5
Скачать (прямая ссылка): antisindrom2004.pdf
Предыдущая << 1 .. 171 172 173 174 175 176 < 177 > 178 179 180 181 182 183 .. 184 >> Следующая

5. Napoleone E, Di Santo A, Camera M, et al. Angiotensin-converting enzyme inhibitors down-regulate tissue factor synthesis in monoyte. Circ Res 2000; 86: 139—143.
SHS-OOO4.qxd 21.11.2006 16:56 Page
ГЛАВА 14. Новые подходы к профилактике и лечению антифосфолипидного синдрома
6. Soejima H, Ogawa H, Yasue H, et al. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocar-dial infarction. J Am Col Cardiol 1999; 34: 983—988.
7. Sadoshima J. Novel AT1 receptor — independent functions of losartan. Circ Res 2002; 90: 754—756.
8. Kramer S, Sunkomat J. Witte J, et al. An-giotensin II receptor — independent antiinflam-matory and antiaggregatory oroperties of losar-tan: role of active metabolite EXP3179. Circ Res 2002; 90: 770—776.
9. Schwemmer M, Sommer O, Bassenge E. Blo-cade of angiotensin signaling improves myocatdi-al function in hypercholesterolemia independent of changes in ecosanoid release. Cardiovasc Drug Ther 2000; 14L 317—327.
10. Maeso R, Rodrigo E, Munoz-Garcia R, et al. Lasartan reduces constrictor responses to endothelin-1 and thromboxane A2 analogue in aortic rings from spontaneously hypertensive rats: role of nitric oxide. J Hypertension 1997; 15: 1677—1684.
11. Bertolino F, Valentin JP, Maffre M, et al. Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angio-tensin II type receptor antagonist. J Pharmacol Exp Ther 1994; 268: 747—752.
12. Li P, Ferrario CM, Brosnihan KB. Nonpe-ptide angiotensin II antagonist losartan inhibits thromboxane A2-induced constrictions in canine coronary artery. J Pharmacol Exp. Ther 1997; 281: 1065—1070.
13. Valentin JP, Jover B, Maffe M, et al. Lozartan prevents thromboxane A2/prostanoid (TP) receptot mediated increase in microvascular permeability in the rat. Am J Hypertension 1997; 10: 1058—1063.
14. Picard P, Chretien L, Couture R. Functional interaction between losartan and central tachykinin NK3 receptors in the conscious rat. Br J Pharmacol 1995; 114: 1563—1570.
15. Li Z, Bosch SM, Smith TL, Diz DI. Interactions of nonpeptide angiotensin II receptor antagonists at imidazoline/guanidinium receptor sites in rat forebrain. J Cardiovasc Pharmacol 1996; 28: 425—431.
Аминохинолиновые препараты (гидроксих-лорохин)
1. Насонов ЕЛ, Иванова ММ. Антималярийные (аминохинолиновые) препараты: новые фармакологические свойства и перспективы клинического применения Клин. фарма-кол. терапия, 1998; 3: 65—68.
2. Wallace DJ. The use of chloroquine and hydroxychloroquine for non-infections conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 1996; 5 (Suppl 1): S59—S64.
3. Janicinova V, Nassal R, Petrikova M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb Res 1995; 77: 531—542.
4. Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythe-matosus? Arthritis Rheum 1987; 30:1435—1456.
5. Wallace DJ, Linker-Israeli M, Metzger AL, Stecher VJ. The revalence of antimalarial therapy with regard thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 1993; 2 (Suppl 1): S13—S15.
6. Petri M, Hochberg M, Hellmann D, et al. Incidence and predictors of thrombotic events in SLE: protective role of hydroxychloroquine. Arthritis Rheum 1992; 35 (Suppl 9):S54.
7. McCarty. Hydroxychloroquine treatment in antiphospholipid antibody syndrome: time course of clinical improvement and antiphpspholipid antibody titer changes over 4 years. Arthritis Rheum 2000; 43 (Suppl): 9: S1061.
8. Edwards MH, Pierangeli S, Liu XW, et al. Hydroxychloroquine reserves thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997; 96: 4380—4384.
9. Cho C-S, Cho M-L, Min S-Y, et al. Hydroxy-chloroquine inhibits the production of monocyte chemoattractant protein 1 in endothelial cell. Implication of its therapeutic use in antiphospholipid syndrome. ACR/ARHP Annual Scientific Meeting, Orlando, October 24—28, 2003; 321 (abst).
10. Espinola RG, Pierangeli SS, Ghara AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospho-lipid antibodies. Thromb Haemost 2002; 87: 518—522.
11. Beynen AC. Can chloroquine be of value in the treatment of hypercholesterolemia? Artery 1986; 13: 340—351.
SHS-OOO4.qxd 21.11.2006 16:56 Page
Насонов Е.Л. Антифосфолипидный синдром.
12. Svenson KLG, Lithell H, Hillgren R, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides.II Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med 1987; 147: 1917—1920.
13. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipid, glucose and thrombosis. Lupus 1996; 5 Suppl 1: 16—22.
14. Wallace DJ, Metzger AL, Stecher VJ, et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deletetious effects of steroid on lipid. Am J Med 1990; 89: 322—326.
Предыдущая << 1 .. 171 172 173 174 175 176 < 177 > 178 179 180 181 182 183 .. 184 >> Следующая

Реклама

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed

Есть, чем поделиться? Отправьте
материал
нам
Авторские права © 2009 BooksShare.
Все права защищены.
Rambler's Top100

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed